Insights & News

Industry Frontier | ASN 2026 Complement Research Update

Tissue targeting · mechanism matching · activity assessment—from 68 core complement-related abstracts, what kidney disease research is asking.

Research Publications

View AlloDx collaborative research papers and literature links.

Guidelines for Immune Monitoring in Kidney Transplantation: A Focus on Prevention

In recent years, with the steady increase in the number of organ donations and transplants, my country has become the second largest country in organ transplantation in the world, with kidney…

Good news! Expert consensus on the clinical application of donor-derived cell-free DNA detection in kidney transplantation (2022 version) is officially online

Recently, the "Expert Consensus on the Clinical Application of Donor-derived Cell-free DNA Detection in Kidney Transplantation" (2022 Edition) was officially released online in the Chinese Journal of…

AlloDx makes new progress in non-invasive research on bladder cancer based on urine cfDNA copy number variation analysis

Bladder cancer is one of the common malignant tumors worldwide. Currently, its clinical diagnosis mainly relies on invasive methods such as cystoscopy. Although it has diagnostic value, it has…

High-resolution HLA genotyping technology helps improve transplant matching accuracy

The AlloDx R&D team, together with the Xuzhou Municipal Hospital Affiliated to Xuzhou Medical University and the School of Life Sciences of Jiangsu University, successfully broke through the…

Professor Wang Rending’s team from the First Hospital of Zhejiang University discovered a new marker for monitoring BKV nephropathy: simultaneous measurement of urine and plasma dd-cfDNA can assist in the adjustment of immunosuppressants in kidney transplant patients

Professor Wang Rending’s team from the First Affiliated Hospital of Zhejiang University School of Medicine has recently made important scientific research breakthroughs. A prospective cohort study…

Scientific research results | Clinica Chimica Acta published an article: A new non-invasive BK virus-related nephropathy detection technology

Recently, AlloDx (AlloDx Biotech), together with Jiangsu University, Tongji Hospital Affiliated to the School of Medicine of Huazhong University of Science and Technology and other institutions,…

Scientific research results | The research results related to AlloDx donor-derived cell-free DNA were published in Kidney Research and Clinical Practice magazine

Recently, AlloDx conducted another study on donor-derived cell-free DNA, "Donor-derived cell-free DNA-based liquid biopsies to determine future kidney transplant rejec

Scientific research results | AlloDx's research article on the analysis of factors affecting the detection of donor-derived cell-free DNA is officially published

Recently, an important result of the AlloDx research team - Analysis of the primary factors influencing donor derived cell-free DNA testing in kidney transplant

Research in the Journal of Zhejiang University Identifies a Biomarker to Distinguish BKVAN from TCMR

With the use of highly effective immunosuppressants, infection after kidney transplantation is one of the main problems faced by patients, especially BK virus-related nephropathy, which is one of the…

dd-cfDNA is a biomarker for accurate diagnosis of kidney transplant antibody-mediated rejection (ABMR)

Recently, the Nephrology Center of the General Hospital of Eastern Theater Command collaborated with the AlloDx Medical Department, using the AlloDx AlloK seqTM [Ankang] non-invasive kidney…

A Nature Portfolio Journal Cites the AlloDx Team's Early dd-cfDNA Research

Recently, the AlloDx team's early paper on the detection technology of kidney transplant donor-derived cell-free DNA (dd-cfDNA) was cited once by a Nature sub-journal published in May.

Published by Clinical Transplantation | The value of dd-cfDNA in evaluating acute rejection treatment

Recently, important research results jointly conducted by Professor Wang Rending’s team at the Kidney Disease Center of the First Affiliated Hospital of Zhejiang University and AlloDx Medical…

Transplantation Proceedings | AlloDx joins hands with domestic organ transplant experts to develop a new method for detecting postoperative rejection and infection in organ transplant patients

In September 2019, the research results on a new method for detecting rejection and infection in organ transplant patients, jointly led by the School of Life Sciences of Jiangsu University, the…

[Published by TRANSPL INT] The first domestic post-transplant liquid biopsy data published

Recently, "Transplant International", a well-known international journal in the field of transplantation, published online a study conducted by our company and the team of Director Wang Rending of…

AlloDx Kidney Transplant dd-cfDNA Research Cited in a Nature Portfolio Journal

A paper by the AlloDx team at the center's collaborating unit on kidney transplant donor-derived cell-free DNA (dd-cfDNA) testing technology was cited once by a Nature sub-journal published in May. AlloDx was among the early to perform kidney transplant donor-derived dd-cfDNA testing, and related technical papers have been cited by international authoritative journals

Nature Study Maps Immune Responses to Pig Kidney Xenotransplantation

Facing the global organ shortage crisis, gene-edited pig organs are seen as a beacon of hope for saving lives. However, even after gene editing, the strong immune rejection after cross-species…

Prospective case: follow-up of a preoperative Nephrin antibody-positive patient after desensitization treatment

Recently, the magazine "Kidney International" reported a case of a pediatric patient with primary focal segmental glomerulosclerosis (pFSGS) who cleared Nephrin antibodies before kidney…

Frontiers of Xenotransplantation | NEJM Case Report: Gene-edited pig kidney xenotransplantation brings new hope to patients with end-stage renal disease

Recently, the New England Journal of Medicine (NEJM) published a xenotransplantation case report from Massachusetts General Hospital in the United States. Researchers at the hospital successfully…

Industry Frontier | Pig kidney-derived cell-free DNA (xd-cfDNA) enables early warning of xenogeneic kidney transplant rejection

Recently, a study published in the journal Xenotransplantation provides a new and important direction for postoperative monitoring of kidney xenotransplantation. The study was completed by a team of…

2022ATC in-depth interpretation (3): Factors affecting dd-cfDNA detection values

As dd-cfDNA enters the clinical application stage of transplantation, it is necessary to correctly interpret the clinical significance of the detection values. On the one hand, we are required to…

2022ATC in-depth interpretation (2): In-depth correlation analysis between dd-cfDNA detection and Banff pathological indicators

In studies pairing donor-derived cell-free DNA (dd-cfDNA) detection with biopsy pathology, dd-cfDNA has been shown to be diagnostic of rejection. With the deepening of research, clinical trials have…

ATC2022 in-depth interpretation (1): dd-cfDNA clinical usage scenarios and usage experience summary

As the clinical application of dd-cfDNA in kidney transplantation continues to expand, transplant centers around the world continue to deepen their understanding of the synergistic value between…

ATC2022 Review: In-depth interpretation of global progress of dd-cfDNA

From June 4 to 8, the five-day American Transplantation Conference (ATC) was held in Boston, USA. The conference had a forward-looking theme of "The Science of Tomorrow Starts Today" and covered many…

Industry Frontier | Am J Transplant magazine research results reveal the similarities and differences between DSA-positive and DSA-negative mABMR at the clinical manifestations, pathological biopsy and molecular level

On May 16, the American Journal of Organ Transplantation (Am J Transplant) published the results of a study online. The study compared the clinical manifestations, pathological biopsy and…

Industry Frontier | Researchers transform type A blood donor lungs into universal blood type donor lungs through enzymatic treatment

Recently, Canadian researchers say they have found a way to help people who would otherwise languish on the organ transplant list. In their new study, they detail converting lungs from people with…

ATC 2021: dd-cfDNA for Subclinical Screening (Part 3)

The clinical manifestations of subclinical rejection are not obvious, and procedural biopsy is currently the main method to detect subclinical rejection. However, its application is limited due to…

ATC 2021: dd-cfDNA, Risk Stratification and Prognosis (Part 2)

At present, research on donor-derived cell-free DNA (dd-cfDNA) mainly focuses on the diagnosis of rejection, but there are few reports on its use for prognostic factor analysis and risk…

ATC 2021: Perspectives on Donor-derived Cell-free DNA (Part 1)

At this year's American Transplantation Annual Conference (ATC 2021), donor-derived cfDNA (dd-cfDNA), an emerging biomarker in the field of transplantation liquid biopsy, continues to become a…

Transpl Infect Dis: COVID-19 survivors may be safe organ donors

The new coronavirus has been raging around the world for 18 months since it was first reported. While the virus poses a huge threat to human life, it has also profoundly affected the global…

"Nature Reviews Nephrology" published a review: dd-cfDNA can be used to detect kidney transplant damage

Recently, the international authoritative medical journal Nature Reviews Nephrology published a review focusing on the transplant liquid biopsy biomarker—dd-cfDNA. It proposes that clinical…

New York State approves Eurofins Viracor new kidney transplant rejection biomarker test

Eurofins Viracor and Transplant Genomics stated that the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) has approved the company's Viracor TRAC donor-derived…

Industry Frontier | The impact of urinary tract infection on dd-cfDNA detection values

Urinary tract infection is one of the most common infections after kidney transplantation, with an incidence rate of 20%-80% after transplantation. Studies have suggested that urinary tract infection…

Industry News | NephroSant launches urine sample-based kidney transplant rejection diagnostic product

About 20% of kidney transplant patients require retransplantation every year, and acute rejection is an important factor affecting the long-term survival of the transplanted kidney. Early and…

Science Frontier: Regarding dd-cfDNA, what was discussed at the ATC meeting? (3)

In the last two issues, the editor introduced to you the new progress of donor-derived cell-free DNA (dd-cfDNA) in transplantation liquid biopsy at the ATC conference. In this issue, the editor will…

Science Frontier: Regarding dd-cfDNA, what was discussed at the ATC meeting? (2)

In the last issue, the editor introduced to you the new progress of transplant liquid biopsy (donor-derived cell-free DNA, dd-cfDNA) at the ATC meeting. In this issue, the editor will continue to…

Science Frontier: Regarding dd-cfDNA, what was discussed at the ATC meeting? (1)

Due to the COVID-19 pandemic in 2020, the American Transplant Congress (ATC), originally scheduled for May 30 to June 3 in Philadelphia, was held online for the first time, presenting cutting-edge…

Industry News | CareDx partners with Weill Cornell Medicine to use urine samples to diagnose acute rejection

Recently, CareDx, a molecular diagnostics company focusing on organ transplantation, announced a strategic alliance with Weill Cornell Medicine to use UroMap detection technology to diagnose T…

Transplant Liquid Biopsy | Molecular Stethoscope for Organ Health Monitoring

Organ transplantation is known as one of the three major application fields in the era of liquid biopsy. It is the next emerging direction of liquid biopsy application after non-invasive prenatal…

CareDx launches cell-free DNA-based non-invasive detection product for kidney transplant rejection

CareDx (CNDA), a Nasdaq-listed company based in California, USA, recently released AlloSure, a non-invasive detection product for rejection after kidney transplantation.

To protect the health of transplanted organs, a cutting-edge company raised tens of millions of dollars in Series A financing!

Emerging name: TAI Diagnostics Company location: Wauwatosa, Wisconsin, USA

He Xiaoshun's team at Sun Yat-Sen First Hospital successfully performed the world's first "no ischemia" kidney transplant

Recently, Professor He Xiaoshun’s team at our hospital’s Organ Transplantation Center successfully performed the world’s first “ischemia-free” kidney transplantation. This is the first time that the…

Biomarker Insights: Why Is C3NeF Difficult to Measure Accurately?

C3NeF is one of the functional drivers of abnormal activation of the alternative complement pathway. The key to measuring it accurately lies in whether the functional status of the invertase can be…

Biomarker Insights: Tracking Donor Cell Dynamics After Cell Infusion

AlloDx has accumulated experience in dd-cfDNA detection methods and application research in the field of transplantation. For allogeneic cell therapy, the Indel detection method with low background…

Biomarker Insights: Which Monoclonal Antibodies Can Accurately Measure sC5b-9?

AlloDx CompliTCC™ is based on independently developed AD99 and improves selectivity for complete sC5b-9 complexes from the antibody epitope level.

Why Is sC5b-9 Difficult to Measure Accurately?

The complement system has three entrances but only one common terminal exit. The classical pathway, the lectin pathway, and the alternative pathway can be initiated by different triggers, but…

Cutting-edge markers | BAFF and APRIL: What is the clinical exploration value of "source indicators" in the pathogenesis of IgA nephropathy?

The clues to the cause of IgA nephropathy (IgAN) may be hidden in two names - BAFF and APRIL. As B cell activating factor (BAFF) and proliferation-inducing ligand (APRIL), they are the "upstream…

Application of Nephrin Antibodies in Kidney Transplantation

Recurrence of focal segmental glomerulosclerosis (FSGS) after renal transplantation is a major risk factor for renal allograft failure. Studies have shown that the overall recurrence rate of FSGS…

Growing Interest in Nephrin Antibodies: Choosing a Testing Method

Nephrin antibodies, as a new circulating penetrant factor in podocyte nephropathy, are considered to be of great value in distinguishing MCD (minimal change kidney disease)/FSGS (focal segmental…

Opportunities and challenges of Nephrin research (Part 1)

Recent studies have shown that anti-Nephrin autoantibodies (Anti-nephrin Ab) play an important role in the occurrence of minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS).…

Opportunities and challenges of Nephrin research (Part 2)

Prior to the identification and sequencing of the NPHS1 gene (Nephrin), scientists had begun to explore the characteristics of antibodies that could bind to the glomerular foot process surface and…

Transplant Q&A: When Should Medication Be Adjusted After BK Virus Is Detected in Urine or Blood?

BK virus (BKV) is a common polyomavirus after kidney transplantation. The infection rate among kidney transplant patients reaches 68%. Some patients (1%~10%) are prone to progress to BK virus-related…

Can COVID-19 vaccines be used by transplant patients?

With the new coronavirus (COVID-19) vaccine on the market, more and more immigrants are concerned about whether they can use the COVID-19 vaccine? Here, the editor combines the vaccine use FAQs and…

Zhang Yimou's Public-interest Film on Five Years of Organ Donation and Transplantation in China

--> -->

CCTV Public-service Video on Organ Transplantation

--> -->

AlloDx launches CompliTCC™ sC5b-9 test

AlloDx launches CompliTCC™ sC5b-9 test

AlloDx CompliNeF™ Assay: Reading C3NeF Function Through Bb Retention

2026-09-23 A reliable C3NeF assay must both reflect changes in C3 convertase function and minimize interference from anti-IgG signals. If C3NeF is treated as an ordinary auto

Genetic testing should not stop at finding mutations

Core point of view: Detecting variants is only the starting point; only by putting the variants back into the context of kidney disease and kidney transplantation can we form more clinically valuable…

AlloDx SuperNAT: Advancing Nephrin Antibody Testing in Podocyte Disease

In recent years, Nephrin antibodies have attracted increasing attention from the nephrology community as potential biomarkers for podocyte-related diseases such as minimal change disease (MCD) and…

AlloDx releases SuperNAT: a new generation of highly sensitive Nephrin antibody test

Recently, AlloDx launched a self-developed second-generation highly sensitive Nephrin antibody detection solution - Super Nephrin AntibodyTrap (SuperNAT for short), which can be used to detect…

dd-cfDNA quantitative technology upgrade!

dd-cfDNA is a biomarker of non-invasive injury in kidney transplantation. Its detection accuracy is affected by specific pathological/physiological conditions, such as the patient's pregnancy, tumor…

New: Comprehensive Genetic Testing for Alport Syndrome

Alport syndrome (AS), also known as hereditary progressive nephritis, is a primary glomerular basement membrane disease caused by mutations in the gene COL4An (n=3, 4, 5) encoding the α3-α5 chain of…

AlloDx Patents

Invention name: An immunomagnetic bead and its application in isolation of renal tubular epithelial cells Patent number: ZL 2021 1 0988884.6 Invention name: A method for detecting ultra-low-frequency mutations in cfDNA

Good news | The national “Science and Technology Innovation 2030 Major Project” jointly applied for by Zhejiang University, Wuxi People’s Hospital, AlloDx and others was officially launched

Recently, the National Science and Technology Innovation 2030 - "Research on the Prevention and Treatment of Cancer, Cardio-Cerebrovascular, Respiratory and Metabolic Diseases" major project…

Seminar on clinical application progress of donor-derived cell-free DNA was successfully held

On March 30, an online seminar on clinical application progress of donor-derived cell-free DNA (hereinafter referred to as dd-cfDNA) hosted by AlloDx was successfully held. With the theme of "Joining…

AlloDx and Aishen.com have reached a strategic cooperation to provide more comprehensive services to patients with kidney disease.

Recently, AlloDx and Aishen.com have reached a strategic cooperation - announcing that the two parties will establish an in-depth cooperative relationship in Internet medical care, giving full play…

The company cooperates with many domestic tertiary hospitals to carry out product academic promotion activities

In order to improve clinical transplantation experts' awareness of the company's "Oin M1" product, and further collect feedback on the current use of clinical products. Recently, our company has…

AlloDx to Showcase Three Innovative Assay Kits at ASN Kidney Week 2026

On October 22–24, 2026, AlloDx will bring three key assay kits — anti-Nephrin autoantibody, sC5b-9 and C3NeF — to the ASN Kidney Week 2026 scientific exhibition in Denver, USA, exchanging progress in…

AlloDx SuperNAT Draws International Interest at WCN 2026

On March 31, the 31st World Congress of Nephrology (WCN 2026) concluded successfully in Yokohama, Japan. This four-day conference, with scientific and technological innovation and global…

Four AlloDx Studies, Including SuperNAT Research, Selected for WCN 2026

The 2026 World Congress on Nephrology (WCN 2026) will be held from March 28 to 31 at Pacifico Yokohama, Japan. As an important academic conference in the field of global kidney disease, this…

AlloDx Showcases Nephrin Antibody Kits and Other Innovations at the 16th Taizhou Medical Expo

From November 28th to 30th, the 16th Taizhou Pharmaceutical Expo was successfully held at the China Medical City Convention and Exhibition Trading Center. As a high-profile industry event in the…

AlloDx Presents Two Innovative Studies at ASN 2025

Recently, the ASN Kidney Week (Kidney Week 2025)—an academically influential event in the global nephrology field—concluded successfully in Houston, USA. As a bellwether guiding global kidney disease…

AlloDx Presents Research Advances at Major Scientific Meetings

In the golden autumn of October, the harvest season, two authoritative academic events in the field of nephrology and organ transplantation in China - the 28th Academic Annual Meeting of the Chinese…

AlloDx and Clinical Collaborators Present Two Studies at CSOT 2025

The 2025 Academic Annual Conference of the Chinese Society of Organ Transplantation (CSOT 2025), an annual event in the field of domestic organ transplantation medicine, was grandly held in…

AlloDx Presents Two Research Posters at CCSN 2025

On October 22, the 28th Academic Annual Conference of the Nephrology Branch of the Chinese Medical Association (CCSN 2025) officially opened at the Zhengzhou International Convention and Exhibition…

To create a healthy future together, AlloDx debuted at the 15th Taizhou Medical Expo with dd-cfDNA and other products

From November 29th to 30th, the 15th China (Taizhou) International Pharmaceutical Expo (hereinafter referred to as the "Medical Expo") was successfully held at the Taizhou China Medical City…

AlloDx Presents a Multi-site DNA Methylation Model for Predicting SRNS at ASN 2024

The 57th American Society of Nephrology Kidney Week (ASN Kidney Week) has been grandly held in San Diego from October 24th to 27th, 2024, U.S. time. This highest-level industry event in the field of…

The 29th Annual Organ Transplantation Conference of the Chinese Medical Association was successfully held, and AlloDx presented a number of collaborative research results

From October 17 to October 20, 2024, the 29th Chinese Medical Association Annual Conference on Organ Transplantation (CSOT2024) and a series of activities to celebrate the 110th anniversary of the…

AlloDx Multi-site DNA Methylation Model for Predicting SRNS Selected for a Poster at ASN 2024

Recently, research results of AlloDx's R&D team on 'multiplex methylation-site model for predicting SRNS' were invited to the American Society of Nephrology Annual Meeting—an academically influential…

AlloDx Urinary Multi-miRNA Risk Model Research for Early BKVAN Detection Selected for ATC 2024

BK polyomavirus-associated nephropathy (BKVAN) is a kidney disease caused by the human polyomavirus BKV. BKV-DNA copy number, SV40 immunohistochemistry staining and dd-cfDNA in hematuria are…

AlloDx Liver Transplant cfDNA Fragmentomics Research Selected for ATC 2024

The 2024 American Organ Transplantation Conference will be held in Philadelphia, Pennsylvania, USA, from June 1st to 5th (Eastern Time). The AlloDx R&D team is honored to be invited to give a poster…

The 2023 Chinese Medical Association Annual Conference on Organ Transplantation (CSOT) concluded successfully

The "2023 Chinese Medical Association Organ Transplantation Annual Conference" sponsored by the Chinese Medical Association and the Organ Transplantation Branch of the Chinese Medical Association and…

[TTS] AlloDx research results unveiled at World Organ Transplantation Conference

[2020 TTS] Three research results jointly conducted by clinical experts and AlloDx will be presented at the TTS online annual meeting

Affected by the global COVID-19 epidemic, the 28th World Transplantation Conference (TTS) originally scheduled to be held in Seoul, South Korea, was changed to an online conference from September 13…

AlloDx at the 2019 China Organ Transplantation Conference

On August 2, 2019, the 2019 China Organ Transplantation Conference and the 6th China Organ Transplant Physicians Annual Conference were grandly held at the Baiyun International Conference in…

AlloDx to Present Five Studies at ESOT

The 19th European Society for Organ Transplantation (ESOT) Congress will be held in Copenhagen, Denmark, from September 15th to 18th, 2019. The content of this conference will cover all fields of…

AlloDx Presents Products and Research at CSOT 2018

The 2018 Organ Transplantation Annual Conference of the Chinese Medical Association was held from October 26 to 28, 2018, at the Yanqi Lake International Convention and Exhibition Center in Beijing.

AlloDx to Present Its Latest Research at ATC 2019

June 1–5, the 2019 Annual Meeting of the American Transplant Congress (ATC)—one of the most renowned and large-scale transplantation annual meetings in the global organ transplantation field—will be…

AlloDx Presents Organ Transplant Liquid Biopsy Research at ATC 2018

The American Transplant Congress (ATC) was held in Seattle, USA from June 1-6, 2018. Dr. Yang Gongda of the company was invited to participate in this grand event in the field of global organ…

AlloDx was awarded Shanghai’s “High-tech Enterprise” certification

Recently, Shanghai AlloDx Technology Co., Ltd. successfully passed the relevant regulations on the recognition of high-tech enterprises in the "High-tech Enterprise Recognition Management Measures",…

AlloDx "Liquid Biopsy Solution for Organ Transplantation" was approved by the Technology Innovation Funding Program for small and medium-sized technology enterprises

Recently, the Shanghai Municipal Science and Technology Commission officially announced the list of companies in the "Shanghai 2021 Technology Innovation Funding Plan for Small and Medium-sized…

AlloDx won the second prize in the Venture Capital Huizhi·Xiacheng District Innovation and Entrepreneurship Competition

On the afternoon of December 15, the Venture Capital Huizhi·Xiacheng District Innovation and Entrepreneurship Competition and the Third Angel Dream Fund Entrepreneurship Competition Finals were…

Good news | Our company won the third prize in the team group of the "2018 Biomedical Innovation and Entrepreneurship Competition-Shenzhen Yantian District Preliminary Competition"!

On the afternoon of June 28, the Yantian District Qualifiers of the 10th China Shenzhen Innovation and Entrepreneurship Competition and the 2018 Biomedical Innovation and Entrepreneurship Competition…